Markets by TradingView

Browsing Tag

pericarditis

14 posts

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in…

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Topline Results Expected in Q2 2024 This is a Designated News Release.…

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company’s…

Distinguished Health Centers and Experts Lead Recurrent Pericarditis, Acute Myocarditis Clinical Trials 

Any clinical trial program relies heavily on its administrators, advisors, and designers.…

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Toronto, Ontario–(Newsfile Corp. – January 9, 2024) – Cardiol Therapeutics Inc. (NASDAQ: CRDL)…

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

MAvERIC-Pilot is a Phase II Study in Recurrent Pericarditis and is Anticipated…

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Toronto, Ontario–(Newsfile Corp. – November 16, 2023) – Cardiol Therapeutics Inc. (NASDAQ: CRDL)…